NEW YORK (GenomeWeb News) – Nuvera Biosciences has licensed pharmacogenomic assays that it has developed to Veridex, which will commercialize the tests.

The multi-gene assays were developed for predicting patient response to tamoxifen therapy and taxane-containing chemotherapy in breast cancer. Woburn, Mass.-based Nuvera developed the assays in collaboration with the University of Texas MD Anderson Cancer Center.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.